Archived HIV-1 Drug Resistance Mutations: Role of Proviral HIV-1 DNA Genotype for the Management of Virological Responder People Living with HIV
Open Access
Abstract
Despite its effectiveness in controlling plasma viremia, antiretroviral therapy (ART) cannot target proviral DNA, which remains an obstacle to HIV-1 eradication. When treatment is interrupted, the reservoirs can act as a source of viral rebound, highlighting the value of proviral DNA as an additional source of information on an individual’s overall resistance burden. In cases where the viral load is too low for successful HIV-1 RNA genotyping, HIV-1 DNA can help identify resistance mutations in treated individuals. The absence of treatment history, the need to adjust ART despite undetectable viremia, or the presence of LLV further support the use of genotypic resistance tests (GRTs) on HIV-1 DNA. Conventionally, GRTs have been achieved through Sanger sequencing, but the advances in NGS are leading to an increase in its use, allowing the detection of minority variants present in less than 20% of the viral population. The clinical significance of these mutations remains under debate, with interpretations varying based on context. Additionally, proviral DNA is subject to APOBEC3-induced hypermutation, which can lead to defective, nonviable viral genomes, a factor that must be considered when performing GRTs on HIV-1 DNA.Keywords
This publication has 136 references indexed in Scilit:
- Validation of an HIV whole genome sequencing method for HIV drug resistance testing in an Australian clinical microbiology laboratoryJournal of Medical Virology, 2023
- HIV DNA Sequencing to Detect Archived Antiretroviral Drug ResistanceInfectious Diseases and Therapy, 2022
- Overview of Next‐Generation Sequencing TechnologiesCurrent Protocols in Molecular Biology, 2018
- AID recruits the RNA exosome to degrade HIV-1 nascent transcripts through interaction with the Tat-P-TEFb-TAR RNP complexFEBS Letters, 2018
- Comparison of HIV-1 drug-resistance genotyping by ultra-deep sequencing and sanger sequencing using clinical samplesJournal of Medical Virology, 2017
- An analog of camptothecin inactive against Topoisomerase I is broadly neutralizing of HIV-1 through inhibition of Vif-dependent APOBEC3G degradationAntiviral Research, 2016
- Replication-Competent Noninduced Proviruses in the Latent Reservoir Increase Barrier to HIV-1 CureCell, 2013
- Stepping stones in DNA sequencingBiotechnology Journal, 2012
- Direct evidence that RNA inhibits APOBEC3G ssDNA cytidine deaminase activityBiochemical and Biophysical Research Communications, 2011
- Antiretroviral genotypic resistance in plasma RNA and whole blood DNA in HIV‐1 infected patients failing HAARTJournal of Medical Virology, 2008